513 related articles for article (PubMed ID: 30690043)
21. An overview of letermovir: a cytomegalovirus prophylactic option.
Gerna G; Lilleri D; Baldanti F
Expert Opin Pharmacother; 2019 Aug; 20(12):1429-1438. PubMed ID: 31282759
[No Abstract] [Full Text] [Related]
22. In vitro drug combination studies of Letermovir (AIC246, MK-8228) with approved anti-human cytomegalovirus (HCMV) and anti-HIV compounds in inhibition of HCMV and HIV replication.
Wildum S; Zimmermann H; Lischka P
Antimicrob Agents Chemother; 2015; 59(6):3140-8. PubMed ID: 25779572
[TBL] [Abstract][Full Text] [Related]
23. A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance.
Chou S
Antiviral Res; 2017 Dec; 148():1-4. PubMed ID: 29107686
[TBL] [Abstract][Full Text] [Related]
24. Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds.
Chou S
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28827420
[TBL] [Abstract][Full Text] [Related]
25. Artemisone demonstrates synergistic antiviral activity in combination with approved and experimental drugs active against human cytomegalovirus.
Oiknine-Djian E; Bar-On S; Laskov I; Lantsberg D; Haynes RK; Panet A; Wolf DG
Antiviral Res; 2019 Dec; 172():104639. PubMed ID: 31654672
[TBL] [Abstract][Full Text] [Related]
26. Phenotypic characterization of two naturally occurring human Cytomegalovirus sequence polymorphisms located in a distinct region of ORF UL56 known to be involved in in vitro resistance to letermovir.
Goldner T; Zimmermann H; Lischka P
Antiviral Res; 2015 Apr; 116():48-50. PubMed ID: 25637709
[TBL] [Abstract][Full Text] [Related]
27. Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir.
Chou S
Rev Med Virol; 2008; 18(4):233-46. PubMed ID: 18383425
[TBL] [Abstract][Full Text] [Related]
28. The chemical class of quinazoline compounds provides a core structure for the design of anticytomegaloviral kinase inhibitors.
Hutterer C; Hamilton S; Steingruber M; Zeitträger I; Bahsi H; Thuma N; Naing Z; Örfi Z; Örfi L; Socher E; Sticht H; Rawlinson W; Chou S; Haupt VJ; Marschall M
Antiviral Res; 2016 Oct; 134():130-143. PubMed ID: 27515131
[TBL] [Abstract][Full Text] [Related]
29. Cytomegalovirus UL97 kinase mutations that confer maribavir resistance.
Chou S; Wechel LC; Marousek GI
J Infect Dis; 2007 Jul; 196(1):91-4. PubMed ID: 17538888
[TBL] [Abstract][Full Text] [Related]
30. Phenotype and Genotype Study of Novel C480F Maribavir-Ganciclovir Cross-Resistance Mutation Detected in Hematopoietic Stem Cell and Solid Organ Transplant Recipients.
Santos Bravo M; Plault N; Sánchez Palomino S; Mosquera Gutierrez MM; Fernández Avilés F; Suarez Lledo M; Sabé Fernández N; Rovira M; Alain S; Marcos Maeso MÁ
J Infect Dis; 2021 Sep; 224(6):1024-1028. PubMed ID: 33475730
[TBL] [Abstract][Full Text] [Related]
31. Maribavir: a novel antiviral agent with activity against cytomegalovirus.
Trofe J; Pote L; Wade E; Blumberg E; Bloom RD
Ann Pharmacother; 2008 Oct; 42(10):1447-57. PubMed ID: 18698013
[TBL] [Abstract][Full Text] [Related]
32. Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo.
Chou S; Hakki M; Villano S
Antiviral Res; 2012 Aug; 95(2):88-92. PubMed ID: 22664236
[TBL] [Abstract][Full Text] [Related]
33. New Insights into Human Cytomegalovirus pUL52 Structure.
Muller C; Alain S; Gourin C; Baumert TF; Ligat G; Hantz S
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452502
[TBL] [Abstract][Full Text] [Related]
34. Emergence of Letermovir-resistant HCMV UL56 mutant during rescue treatment in a liver transplant recipient with ganciclovir-resistant infection HCMV: a case report.
Paolucci S; Campanini G; Cassaniti I; Tebaldi A; Novazzi F; Fratini A; Meini A; Girelli F; Palumbo L; Plebani A; Baldanti F
BMC Infect Dis; 2021 Sep; 21(1):994. PubMed ID: 34556034
[TBL] [Abstract][Full Text] [Related]
35. Letermovir for prophylaxis of cytomegalovirus manifestations in adult allogeneic hematopoietic stem cell transplant recipients.
Hecke SV; Calcoen B; Lagrou K; Maertens J
Future Microbiol; 2019 Feb; 14():175-184. PubMed ID: 30644320
[TBL] [Abstract][Full Text] [Related]
36. Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure.
Goldner T; Hempel C; Ruebsamen-Schaeff H; Zimmermann H; Lischka P
Antimicrob Agents Chemother; 2014; 58(1):610-3. PubMed ID: 24189264
[TBL] [Abstract][Full Text] [Related]
37. Maribavir use in practice for cytomegalovirus infection in French transplantation centers.
Alain S; Revest M; Veyer D; Essig M; Rerolles JP; Rawlinson W; Mengelle C; Huynh A; Kamar N; Garrigue I; Kaminski H; Segard C; Presne C; Mazeron MC; Avettant-Fenoël V; Lecuit M; Lortholary O; Coaquette A; Hantz S; Leruez-Ville M; Ploy MC
Transplant Proc; 2013 May; 45(4):1603-7. PubMed ID: 23726629
[TBL] [Abstract][Full Text] [Related]
38. Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients.
Avery RK; Marty FM; Strasfeld L; Lee I; Arrieta A; Chou S; Tatarowicz W; Villano S
Transpl Infect Dis; 2010 Dec; 12(6):489-96. PubMed ID: 20682012
[TBL] [Abstract][Full Text] [Related]
39. Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant.
Chou S; Marousek GI
J Virol; 2008 Jan; 82(1):246-53. PubMed ID: 17942550
[TBL] [Abstract][Full Text] [Related]
40. The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase.
Goldner T; Hewlett G; Ettischer N; Ruebsamen-Schaeff H; Zimmermann H; Lischka P
J Virol; 2011 Oct; 85(20):10884-93. PubMed ID: 21752907
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
